KR20230119022A - 트라이아진 유도체를 함유하는 경구 투여하는 제제 - Google Patents

트라이아진 유도체를 함유하는 경구 투여하는 제제 Download PDF

Info

Publication number
KR20230119022A
KR20230119022A KR1020237025438A KR20237025438A KR20230119022A KR 20230119022 A KR20230119022 A KR 20230119022A KR 1020237025438 A KR1020237025438 A KR 1020237025438A KR 20237025438 A KR20237025438 A KR 20237025438A KR 20230119022 A KR20230119022 A KR 20230119022A
Authority
KR
South Korea
Prior art keywords
formula
compound represented
vii
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237025438A
Other languages
English (en)
Korean (ko)
Inventor
마사토 고미
겐스케 호리우치
마사유키 모리모토
게이스케 다카가키
Original Assignee
시오노기 앤드 컴파니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202211151791.9A external-priority patent/CN116514734A/zh
Application filed by 시오노기 앤드 컴파니, 리미티드 filed Critical 시오노기 앤드 컴파니, 리미티드
Publication of KR20230119022A publication Critical patent/KR20230119022A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020237025438A 2021-11-24 2022-11-22 트라이아진 유도체를 함유하는 경구 투여하는 제제 Pending KR20230119022A (ko)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
JPJP-P-2021-189932 2021-11-24
JP2021189932 2021-11-24
JPJP-P-2021-191635 2021-11-26
JP2021191635 2021-11-26
JP2022006725 2022-01-19
JPJP-P-2022-006725 2022-01-19
JPJP-P-2022-012386 2022-01-28
JP2022012386 2022-01-28
JPJP-P-2022-017132 2022-02-07
JP2022017132 2022-02-07
JP2022027629 2022-02-25
JPJP-P-2022-027629 2022-02-25
JPJP-P-2022-046304 2022-03-23
JP2022046304 2022-03-23
JP2022142767 2022-09-08
JPJP-P-2022-142767 2022-09-08
CN202211151791.9 2022-09-21
CN202211151791.9A CN116514734A (zh) 2021-11-24 2022-09-21 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
PCT/JP2022/043092 WO2023027198A1 (ja) 2021-11-24 2022-11-22 トリアジン誘導体を含有する経口投与する製剤

Publications (1)

Publication Number Publication Date
KR20230119022A true KR20230119022A (ko) 2023-08-14

Family

ID=85321709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237025438A Pending KR20230119022A (ko) 2021-11-24 2022-11-22 트라이아진 유도체를 함유하는 경구 투여하는 제제

Country Status (6)

Country Link
US (1) US20240148741A1 (https=)
EP (1) EP4289432A4 (https=)
JP (2) JP7253866B1 (https=)
KR (1) KR20230119022A (https=)
AU (1) AU2022333823A1 (https=)
WO (1) WO2023027198A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
LT4122926T (lt) 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
EP4289432A4 (en) * 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
WO2023193818A1 (zh) * 2022-04-08 2023-10-12 湖北九康通生物医药有限公司 一种多取代三嗪烷类化合物的合成方法
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
CN116554106A (zh) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法
CN116589410B (zh) * 2023-05-29 2024-05-03 济南国鼎医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法
CN116621817B (zh) * 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092966A1 (ja) 2009-02-13 2010-08-19 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
WO2013089212A1 (ja) 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物
WO2014200078A1 (ja) 2013-06-14 2014-12-18 塩野義製薬株式会社 アミノトリアジン誘導体およびそれらを含有する医薬組成物
WO2021205298A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19
WO2021250648A1 (en) 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036410A1 (en) * 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
EP4282420A4 (en) * 2021-01-20 2024-11-27 National University Corporation Hokkaido University ANTIVIRAL AGENT
EP4313097A4 (en) * 2021-03-29 2025-03-19 Shireen Nature Company for General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
CN113801097B (zh) 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113666914B (zh) 2021-09-27 2022-06-07 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和用途
CN113773300B (zh) 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113735838B (zh) 2021-09-27 2022-07-08 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092966A1 (ja) 2009-02-13 2010-08-19 塩野義製薬株式会社 新規トリアジン誘導体およびそれを含有する医薬組成物
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012020749A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
WO2013089212A1 (ja) 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物
WO2014200078A1 (ja) 2013-06-14 2014-12-18 塩野義製薬株式会社 アミノトリアジン誘導体およびそれらを含有する医薬組成物
WO2021205298A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and methods for the treatment of covid-19
WO2021250648A1 (en) 2020-09-03 2021-12-16 Pfizer Inc. Nitrile-containing antiviral compounds

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19", Journal of Virology, 2021년 4월 26일, [2022년 2월 15일 검색],
"COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", [online], Johns Hopkins University, [2022년 9월 21일 검색], 인터넷<URL: https://coronavirus.jhu.edu/map.html>
"Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study", [online], 2021년 11월 5일, Pfizer Press Release, [2022년 2월 15일 검색], 인터넷<URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>
"Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)", [online], 2020년 2월 28일, WHO, [2021년 2월 8일 검색], 인터넷<URL: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>
261st Am Chem Soc (ACS) Natl Meet · 2021-04-05/2021-04-16 · Virtual, N/A · Abst 243
ACS Central Science(2021년), 7권, 3호, 467∼475페이지
AIMECS 2021(AFMC International Medicinal Chemistry Symposium 2021), 온라인 심포지엄, 2021년 11월 29일-12월 2일
Arzneimittel-Forschung(1984년), 11권, 6호, 663∼668페이지
bioRxiv preprint doi: https: //doi.org/10.1101/2022.01.26.477782, "Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19"
Cancer Treatment Reviews(1984년), 11권, Supplement 1, 99∼110페이지
Cell Research(2020년), 30권, 678∼692페이지
Contributions to Oncology(1984년), 18권, 221∼234페이지
J. Med. Chem. (2022년), 65권, 6499∼6512페이지, "Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19"
Science(2003년), 300권, 1763∼1767페이지
Science(2020년), 368권, 409∼412페이지
Science(2021년), 374권, 1586∼1593페이지
The NEW ENGLAND JOURNAL of MEDICINE(2020년), 382권, 1564∼1567페이지
인터넷<URL: https://journals.asm.org/doi/10.1128/JVI.01819-20><doi: 10.1128/JVI.01819-20>

Also Published As

Publication number Publication date
JP7253866B1 (ja) 2023-04-07
AU2022333823A1 (en) 2024-05-02
WO2023027198A1 (ja) 2023-03-02
JP7466731B2 (ja) 2024-04-12
US20240148741A1 (en) 2024-05-09
EP4289432A4 (en) 2025-01-15
EP4289432A1 (en) 2023-12-13
JPWO2023027198A1 (https=) 2023-03-02
JP2023078413A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
KR20230119022A (ko) 트라이아진 유도체를 함유하는 경구 투여하는 제제
TWI815396B (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
TWI804933B (zh) 用作cdk7激酶抑制劑的化合物及其應用
CN116514734A (zh) 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
TW202320793A (zh) 含有三嗪衍生物之醫藥組合物
AU2017214589A1 (en) Sulfonamide derivative and pharmaceutical composition containing same
US20250127788A1 (en) Pharmaceutical composition containing triazine derivative
KR20250004704A (ko) 바이러스 증식 저해 활성을 갖는 유라실 유도체 및 그들을 함유하는 의약 조성물
US20250025459A1 (en) Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
CN114787155A (zh) 药物化合物
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN108929329B (zh) 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN116782904A (zh) 含有三嗪衍生物的医药组合物
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
HK40114521A (en) Pharmaceutical composition containing triazine derivative
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
AU2024309726A1 (en) Preparation containing uracil derivative
BR122023002208A2 (pt) Composições farmacêuticas compreendendo derivados de triazina tendo efeito inibidor de propagação de vírus, inibidores e usos
AU2024307335A1 (en) Pharmaceutical composition containing uracil derivative
BR122023002208B1 (pt) Composições farmacêuticas compreendendo derivados de triazina para o tratamento e/ou prevenção de covid-19
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
BR112022023272B1 (pt) Derivados de triazina tendo efeito inibidor de propagação de vírus e cocristal do mesmo com ácido fumárico
HK40098963A (zh) 治疗癌症的方法

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000